Do I write of the emotional impact I experienced when I learned of of my 28-year-old son’s rare disease late in 2013 and the sense of devastation, guilt, loss and anger I felt when he was diagnosed with primary sclerosing cholangitis (PSC)? Do I take a more pragmatic, academic perspective? In truth, both came to the fore after his diagnosis. While searching for evidence-based information on PSC, I spent as much time in tears, confronting the reality of his diagnosis. There is no cure for most rare diseases,1 including PSC; as a mother, this was simply heartbreaking to read.
It is difficult to source Australian data on the incidence and prevalence of PSC, or indeed most of the rare diseases. Current Australian data on the prevalence of PSC are based on research adapted from a 2001 UK study. These data were extrapolated to the 2012 Australian population, providing an estimate of 872 people with PSC that year.2 The only research on PSC I could locate in the academic and grey literature was from the US, UK and European countries.
Epidemiological data are unavailable for the majority of rare diseases worldwide due to the absence of a universally recognised coding system to establish adequate databases.1 With the advent of the International Classification of Diseases 11th Revision (ICD-11), it is anticipated that there will be a mechanism to more accurately gather data on the incidence and prevalence of rare diseases.3 With many thousands of rare diseases, and low incidence and prevalence in each, there is a concomitant lack of researchers working in the field for each specific disease. Difficulties then arise when seeking research collaborations aimed at increasing knowledge and developing treatment options.4
Feeling we were the only people in Australia dealing with PSC, I searched for a support group, to find none existed. In a recent study, two-thirds of patients with rare diseases were not given details of relevant patient support groups.5 It is not hard to see why. With low numbers and diverse geographical spaces where those with a specific rare disease live, the potential for face-to-face support groups is severely hindered. The use of online support groups (OSGs) then becomes a reality as the only available option. A growing body of research on the use and efficacy of OSGs, including a limited amount of research considering rare diseases, is demonstrating overall positive findings.5–7
I am a member of a number of closed Facebook support group pages for PSC and my lived experiences concur with that of the published literature. Information and emotional sharing have been found to be the most frequently sought and offered in OSGs, and are among the strongest features of the OSGs in which I am involved, followed by networking, esteem and, finally, tangible support.6–8 Interestingly, advances in public knowledge and awareness of rare diseases, as well as research funding and legislative changes to support orphan drug development, have derived largely from the strong advocacy of patient support groups.1,9
Many patients (and caregivers) do not receive information about their disease when diagnosed and are left to find their own reliable and accurate information,5 an often difficult task. The usual patient–doctor relationship may become challenged when a rare disease is involved. Given the high number of rare diseases, combined with limited knowledge and treatment options, the general practitioner (GP) is no longer necessarily the expert in this medical encounter, as rare diseases are also uncommon for the GP. Thus, the more ‘traditional’ roles of GP and patient may be disrupted, and the patient/caregiver becomes the expert regarding the disease.10 This disparity could be mitigated by a generic general practice approach to rare diseases as suggested by Knight and Senior.11
A multidisciplinary team is usually required in the management of rare diseases, given the impact on multiple body systems, yet, coordination and communication between health professionals may be arbitrary, with the patient/caregiver being the one to facilitate information-sharing and care. We have taken the lead in our situation, providing an up-to-date, tabled chronology of our son’s complex medical history to each health professional. This details who he has seen and why, and all results and reports for each investigation. This adds to the development and construct of ‘expert’ patient.10
GPs can actively facilitate their patient’s developing expertise. Advising of trustworthy websites, such as Rare Voices Australia, can empower patients to learn more about their disease, enhancing the clinical partnership (Table 1).
Given the beneficial findings of OSGs, together with the lack of face-to-face support groups, it would appear reasonable to suggest Facebook and other social networking websites to newly diagnosed patients. Not all will be interested in support networks, but it is important that they are informed and provided with options for those who do seek additional knowledge and support.
Valmae Ypinazar Dip Teach, BEd (Hons), PhD,Senior Research Fellow, School of Medicine, Griffith University, QLD. firstname.lastname@example.org
Competing interests: None.
Provenance and peer review: Commissioned, externally peer reviewed.
- Schieppati A, Henter J, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet 2008;371:2039–41
- Deloitte. The economic cost and health burden of liver diseases in Australia. Australian Liver Association and Gastroenterological Society of Australia; 2013. Available at https://static1.squarespace.com/static/50ff0804e4b007d5a9abe0a5/t/53321aaee4b09f967eb0c7e5/1395792558684/gesa2013_revised%5B1%5D.pdf [Accessed 18 April 2015].
- Ayme S, Bellet B, Rath A. Rare diseases in ICD11: Making rare diseases visible in health information systems through appropriate coding. Orphanet J Rare Dis 2015;10:35.
- Colledge VL, Solly J. The rare disease challenge and how to promote a productive rare disease community: Case study of Birt-Hogg-Dube Symposia. Orphanet J Rare Dis 2012;7:63.
- Nutt S, Limb L. Survey of patients’ and families’ experiences of rare diseases reinforces calls for a rare disease strategy. Social Care and Neurodisability 2011;2:195–99.
- Coulson NS, Buchanan H, Aubeeluck A. Social support in cyberspace: A content analysis of communication within a Huntington’s disease online support group. Patient Educ Couns 2007;68:173–78.
- Attard A, Coulson NS. A thematic analysis of patient communication in Parkinson’s disease online support group discussion forums. Computers in Human Behavior 2011;28:500–06.
- Roffeei SHM, Abdullah N, Basar N. Seeking social support on Facebook for children with Austism Spectrum Disorders (ASDs). Int J Med Inf 2015;84:375–85.
- Ayme S, Kole A, Graft S. Empowerment of patients: Lessons from the rare diseases community. Lancet 2008;371:2048–51.
- Budych K, Helms TM, Schultz C. How do patients with rare diseases experience the medical encounter? Exploring role behavior and its impact on patient–physician interaction. Health Policy 2012;105:154–64.
- Knight AW, Senior TP. The common problem of rare disease in general practice. Med J Aust 2006;185:82–83.